Navigation Links
Statins have neutral effect on risk of cancer

The cholesterol-lowering medications called statins do not appear to reduce the incidence of cancer or cancer deaths, according to a meta-analysis of previous studies in the January 4 issue of JAMA.

Other studies have suggested that statins reduce the risk of developing cancer, the authors provide as background information in the review article. "Statins have been studied in numerous large-scale, randomized, active- or placebo-controlled trials for primary and secondary prevention of coronary artery disease. In these trials, statins reduced the risk of a first myocardial infarction (heart attack) and overall mortality. With long-term follow-up and collection of cancer data in a majority of studies, insight into the risk of cancer among statin-naïve persons and statin users can be derived," the authors write.

C. Michael White, Pharm.D., from the University of Connecticut and Hartford Hospital, Hartford, Conn., and colleagues, conducted a search of the medical literature from 1966 through July 2005 to identify randomized controlled trials of statins. They found 27 articles (n = 86,936 participants) that met their criteria for inclusion, reporting 26 randomized controlled trials of statins with data on either cancer incidence (n = 20 studies) or cancer death (n = 22 studies).

"In our current meta-analysis, statins did not reduce the incidence of cancer or cancer death," the authors report. "No reductions were noted for cancers of the breast, colon, gastrointestinal tract, prostate, respiratory tract, or skin (melanoma) when statins were used." The authors continue, "?the patients in our meta-analysis were primarily treated with simvastatin and pravastatin. As such, we evaluated pravastatin alone and simvastatin alone on cancer incidence and death and found no impact."

"Statins have a neutral effect on cancer and cancer death risks in randomized controlled trials," the authors write in conclusion. "We could find no type of c ancer that statins benefited or subtype of statin that reduced the risk of cancer.


'"/>

Source:JAMA and Archives Journals


Related biology news :

1. Statins stop hepatitis C virus from replicating
2. Defensins neutralize anthrax toxin
3. Bleach found to neutralize mold allergens
4. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
5. Scientific issues associated with carbon-neutral energy sources such as cellulosic ethanol
6. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
7. Combination therapy boosts effectiveness of telomere-directed cancer cell death
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. Alcohols effects on gene expression in the central nervous system
10. Boosting HIV screening can increase survival and is cost effective
11. Liposome finding implies electrical effect on cell development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology: